Deerfield Management Company LP

Deerfield Management Company LP

Deerfield Management Company LP

Date Founded



780 Third Avenue 37th floor New York, NY, United States

Type of Company


Employees (Worldwide)

101 - 250


Hedge Funds
Hospitals & Patient Services
Private Equity & Venture Capital
Investment Services & Portfolio Management

Company Description

Deerfield Management Co. focuses on investments in growth stocks across the healthcare sector. They target companies with sound fundamentals, long-term earnings growth potential and the potential to capitalize on market trends. Deerfield's approach is based on extensive fundamental research into healthcare sector assets and investment opportunities. They invest mainly in US companies or companies that issue securities available in US public markets. Although this is their focus, there is no geographic limitation on investments and Deerfield may invest outside the US when situations warrant. Their funds generally pursue one of 3 strategies: Large-Cap, Special Situations and Private Design.Deerfield's Large-Cap strategy invests mainly in debt and equity securities, including exchange traded derivative securities, of publicly-traded companies in the healthcare sector. The strategy seeks capital appreciation through a combination of security selection based on fundamental analysis, diversification through investments in stock, debt and derivatives and a mix of long and short positions.The firm's Special Situations strategy emphasizes investments in publicly traded healthcare companies with smaller market-caps. At least 90% of investments must in healthcare companies, and essentially all investments are healthcare related. Investments include equity, debt, royalties or other assets, some of which may have limited liquidity. The strategy makes both long and short investments and may utilize leverage.Deerfield's Private Design strategy invests in public and private healthcare companies using privately created instruments, structures and transactions. This may include, but is not limited to, joint ventures, project financing, contracting for revenue streams, purchasing products/services outright (including intellectual property), participating in LBOs, restructurings and outright buyouts, and developing/participating in the development and sale of therapeutics, medical devices and healthcare products/services.

Contact Data
Trying to get in touch with decision makers at Deerfield Management Company LP? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Managing Partner

Partner & Chief Financial Officer

Partner & General Counsel

Chief Science Officer

Chief Partnership & Communications Officer

Partner, Healthcare Services

Partner, Trading

Partner, Private Transactions



Paths to Deerfield Management Company LP
Potential Connections via
Relationship Science
Deerfield Management Company LP
Recent Transactions
Details Hidden

Flynn Management LLC, Deerfield Management Co. LP (Private Equity) purchase Ablexis LLC from Pfizer Venture Investments, California Technology Ventures, Third Rock Ventures LLC, Numenor Ventures LLC

Transaction Advisors
Legal Advisor

Advised onFlamel Technologies SA purchases Avadel Legacy Pharmaceuticals LLC from Deerfield Management Company LP

Legal Advisor

Advised onFlamel Technologies SA purchases Avadel Legacy Pharmaceuticals LLC from Deerfield Management Company LP

Advisors & Consultants
Legal Advisor

Partner at Katten Muchin Rosenman LLP

Non-Profit Donations & Grants
Details Hidden

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Details Hidden

Xeris Pharmaceuticals, a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Details Hidden

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Deerfield Management Company LP. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Deerfield Management Company LP's profile does not indicate a business or promotional relationship of any kind between RelSci and Deerfield Management Company LP.